---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-006123"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2022-09-16T23:59:59+00:00"
generated_at: "2026-06-23T09:03:45.833012+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CEO J. Melville Engle to retire effective Oct 31, 2022; board initiates successor search

## Summary
- CEO Engle announces retirement, stepping down as Chairman and board member effective October 31, 2022.
- Transition & Separation Agreement provides $524,400 severance (1 yr base salary), $139K pro-rata bonus, and accelerated vesting of 300,000 RSUs.
- Governance committee conducting CEO search; Engle will remain in role through October 31 for orderly transition.
- CFO Bob Myers cited Engle's role in acquiring zPREDICTA and expanding oncology drug development offerings.

## SEC filing metadata
- accession: 0001171843-22-006123
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2022-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184322006123/0001171843-22-006123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184322006123/f8k_091622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-006123
- JSON: https://secwatch.observer/filing/0001171843-22-006123.json
- Plain text: https://secwatch.observer/filing/0001171843-22-006123.txt

## Key facts
- Executive change
  J. Melville Engle departed as Chief Executive Officer at Axe Compute Inc..
  - Action: retire
  - Role: Chief Executive Officer
  source text: On September 15, 2022, J. Melville Engle announced that he will retire as the Chief Executive Officer of Predictive Oncology Inc. (the “Company”) and as Chairman and a member of the Company’s board of directors, effective October 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446159/000117184322006123/0001171843-22-006123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.